The 40 references in paper I. Volkov K., И. Волков К. (2014) “Перспективы применения дорназы альфа в детской респираторной медицине // Perspectives for treatment with dornase-alfa in paediatric respiratory medicine” / spz:neicon:pulmonology:y:2011:i:5:p:97-102

1
Lucas A.M., Douglas L.C.Principles underlying ciliary activity in the respiratory tract. II. A comparison of nasal clearance in man, monkey and other mam-mals. Arch. Otolaryngol. 1934; 20: 518–541.
(check this in PDF content)
2
Sleigh M.Mucus propulsion. In: Crystal R.G., West J.B. et al., eds. The lung: scientific fundations. New York: Raven Press Ltd.; 1991; vol. 1: 189–197.
(check this in PDF content)
3
Nadel J.A. New approaches to regulation of fluid secretion in airways. Chest 1981; 80 (Suppl): 849–851.
(check this in PDF content)
4
Picot R., Das I., Reid L. Pus desoxyribonucleic acid and sputum viscosity. Thorax 1978; 33: 235–242.
(check this in PDF content)
5
Stutts M.J., Canessa C.M., Olsen J.C. et al. CFTR as a cAMP-dependent regulator of sodium channels. Science 1995; 269: 847–850.
(check this in PDF content)
6
Lieberman J. Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis. J.A.M.A. 1968; 205: 312–313.
(check this in PDF content)
7
Shak S., Capon D.J., Hellmiss R. et al. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc. Nat. Acad. Sci. USA 1990; 87: 9188–9192.
(check this in PDF content)
8
Pinder J.C., Gratzer W.B.Investigation of the actin-deoxyribonuclease I interaction using a pyreneconjugated actin derivative. J. Biochem. (Tokyo) 1982; 21: 4886–4890.
(check this in PDF content)
9
Anselmo M.A.,Lands L.C. Cystic fibrosis. In: Pediatric respiratory medicine. St. Louis; 2008. Mosby; 845–907.
(check this in PDF content)
10
Matthews L.W., Spector S., Lemm J., Potter J.L.The overall chemical composition of pulmonary secretions from patients with cystic fibrosis, bronchiectasis, and laryngectomy. Am. Rev. Respir. Dis. 1963; 88: 199–204.
(check this in PDF content)
11
Rozov T., de Oliveira V.Z., Santana M.A. et al. Dornase alfa improves the health-related quality of life among Brazilian patients with cystic fibrosis – a one-year prospective study. Pediatr. Pulmonol. 2010; 45 (9): 874–882.
(check this in PDF content)
12
Капpанов Н.И., Гембицкая Т.Е., Симонова О.И. и др. Опыт длительного применения нового муколитического препарата "Пульмозим" у больных муковисцидо\u000f зом. Тер. арх. 2001; 1: 55–58.
(check this in PDF content)
13
Волков И.К.Возможности использования дорназы альфа (пульмозим) в детской пульмонологии. Пульмонология 2004; 4: 113–117.
(check this in PDF content)
14
Quan J.M., Tiddens H.A.W.M., Sy J.P. et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis and mild lung function abnormalities. J. Pediatr. 2001: 139: 813–820.
(check this in PDF content)
15
Liou T.G., Adler F.R., Fitz Simmons S.C. et al.Predictive 5-year survivorship model of cystic fibrosis. Am. J. Immunol. 2001; 153: 345–352.
(check this in PDF content)
16
Shah P.L., Conway S., Scott S.F. et al.A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4 year period. Respiration 2001; 68: 160–164.
(check this in PDF content)
17
Hodson M.E., McKenzie S., Harms H.K. et al.Dornase alfa in the treatment of cystic fibrosis in Europe: a report from the epidemiologic registry of cystic fibrosis. Pediatr. Pulmonol. 2003; 36 (5): 427–432.
(check this in PDF content)
18
Hodson M.E., Shah P.L. Dnase trials in cystic fibrosis. Eur. Respir. J. 1995; 8: 1786–1791.
(check this in PDF content)
19
Fuchs H.J., Borowitz D.S., Christiansen D.H. et al. Effect of aerosolized recombinant human Dnase on exacerbations of respiratory symptoms and on pulmonary functions in patients whit cystic fibrosis: the Pulmozyme study group. N. Engl. J. Med. 1994; 331: 637–642.
(check this in PDF content)
20
Mainz J.G., Schiller I., Ritschel C. et al. Sinonasal inhalation of dornase alfa in CF: A double-blind placebo-controlled crossover pilot trial. Auris Nasus Larynx 2011; 38 (2): 220–227.
(check this in PDF content)
21
Dentice R., Elkins M. Timing of dornase alfa inhalation for cystic fibrosis. Cochrane Database Syst. Rev. 2011; 5: CD007923.
(check this in PDF content)
22
Jones A.P., Wallis C.E.Dornase alpha for cystic fibrosis. Cochrane Database Syst. Rev. 2010; 3:CD001127.
(check this in PDF content)
23
Kristensen K. Recombinant human DNase in conditions other than cystic fibrosis. Ugeskr. Laeg. 2010; 172 (8): 616–619.
(check this in PDF content)
24
Волков И.К., Давыдова И.В., Куличихин В.Г. и др. Эффективность дорназы альфа (пульмозим) у детей с хроническими заболеваниями легких. Пульмонология 2003; 3: 79–82.
(check this in PDF content)
25
Puchelle E., Zahm J.M., de Bentzmann S. et al.Effects of rhDNase on purulent airway secretions in chronic bronchitis. Eur. Respir. J. 1996; 9 (4): 765–769.
(check this in PDF content)
26
Berge M., Brinkhorst G., Kroon A.A., Jongste J.C. DNase treatment in primary ciliary dyskinesia-assessment by nocturnal pulse oximetry. Pediatr. Pulmonol. 1999; 27: 59–61.
(check this in PDF content)
27
Merkus P.J., de Hoog M., van Gent R., de Jongste J.C. DNase treatment for atelectasis in infants with severe respiratory syncytial virus bronchiolitis. Eur. Respir. J. 2001; 18 (4): 734–737.
(check this in PDF content)
28
Nasr S.Z., Strouse P.J., Soskolne E. et al. Efficacy of recombinant human deoxyribonuclease I in the hospital management of respiratory syncytial virus bronchiolitis. Chest 2001; 120: 203–208.
(check this in PDF content)
29
Kupeli S., Teksam O, Dogru D., Yurdakok M.Use of recombinant human DNase in a premature infant with recurrent atelectasis. Pediatr. Intern. 2003; 45: 584–586.
(check this in PDF content)
30
El Hassan N.O., Chess P.R., Huysman M. et al. Rescue use of DNase in critical lung atelectasis and mucus retention in premature neonates. Pediatrics 2001; 108: 468–471.
(check this in PDF content)
31
Hendriks T., de Hoog M., Lequin M.H. et al.DNase and atelectasis in non-cystic fibrosis pediatric patients. Crit. Care 2005; 9 (4): R35–R356.
(check this in PDF content)
32
Durward A., Forte V., Shemie S.D.Resolution of mucus plugging and atelectasis after intratracheal rhDNase therapy in a mechanically ventilated child with refractory status asthmaticus. Crit. Care Med. 2000; 28 (2): 560–562.
(check this in PDF content)
33
Manna S.S., Shaw J., Tibby S.M. A Durward treatment of plastic bronchitis in acute chest syndrome of sickle cell disease with intratracheal rhDNase. Arch. Dis. Child. 2003; 88: 626–627.
(check this in PDF content)
34
Scherer T., Geller D.E., Owyang L. et al.A technical feasibility study of dornase alfa delivery with eFlow® vibrating membrane nebulizers: aerosol characteristics and physicochemical stability. J. Pharm. Sci. 2011; 100 (1): 98–109.
(check this in PDF content)
35
Bush A. Bronchoscopy in paediatric intensive care. Paediatr. Respir. Rev. 2003: 4 (1): 67–73.
(check this in PDF content)
36
Slattery D.M., Waltz D.A., Denham B. et al. Bronchoscopically administered recombinant human DNase for lobar atelectasis in cystic fibrosis. Pediatr. Pulmonol. 2001; 31 (5): 383–388.
(check this in PDF content)
37
Simpson G., Roomes D., Reeves B.Successful treatment of empyema thoracis with human recombinant deoxyribonuclease. Thorax 2003; 58: 363–366.
(check this in PDF content)
38
Conway S.P.Evidence-based medicine in cystic fibrosis: how should practice change? Pediatr. Pulmonol. 2002; 34: 242–247.
(check this in PDF content)
39
Капранов Н.И., Воронкова А.Ю., Шабалова Л.А. и др. Клиническое значение рекомбинантной человеческой ДНКазы (Пульмозим) в комплексной терапии больных муковисцидозом. Рос. педиатр. журн. 2001; 3: 26–31.
(check this in PDF content)
40
McKenzie S.G., Chowdhury S., Strandvik B., Hodson M.E. Dornase alfa is well tolerated: data from the epidemiologic registry of cystic fibrosis. Pediatr. Pulmonol. 2007; 42 (10): 928–937. Информация об авторе
(check this in PDF content)